Biomarkers /
CRKL
Overview
V-crk avian sarcoma virus CT10 oncogene homolog-like (CRKL) is a gene that encodes a SH2 and SH3 domain containing protein kinase. Missense, nonsense, and silent mutations are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
CRKL is altered in 0.82% of all cancers with lung adenocarcinoma, high grade ovarian serous adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, and cutaneous melanoma having the greatest prevalence of alterations [3].
The most common alterations in CRKL are CRKL Amplification (0.51%), CRKL Mutation (0.30%), CRKL Loss (0.07%), CRKL R164Q (0.02%), and CRKL X104_splice (0.06%) [3].
Clinical Trials
Significance of CRKL in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.